Vertex Pharmaceuticals (VRTX) R&D In Process (2021 - 2025)
Historic R&D In Process for Vertex Pharmaceuticals (VRTX) over the last 5 years, with Q3 2025 value amounting to $54.5 million.
- Vertex Pharmaceuticals' R&D In Process rose 26333.33% to $54.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.0 million, marking a year-over-year decrease of 9640.25%. This contributed to the annual value of $4.6 billion for FY2024, which is 77808.76% up from last year.
- Vertex Pharmaceuticals' R&D In Process amounted to $54.5 million in Q3 2025, which was up 26333.33% from $2.2 million recorded in Q2 2025.
- In the past 5 years, Vertex Pharmaceuticals' R&D In Process ranged from a high of $4.4 billion in Q2 2024 and a low of $2.0 million during Q1 2022
- Moreover, its 5-year median value for R&D In Process was $53.1 million (2023), whereas its average is $358.8 million.
- In the last 5 years, Vertex Pharmaceuticals' R&D In Process soared by 1725500.0% in 2023 and then tumbled by 9995.06% in 2025.
- Over the past 5 years, Vertex Pharmaceuticals' R&D In Process (Quarter) stood at $126.5 million in 2021, then crashed by 82.13% to $22.6 million in 2022, then fell by 21.24% to $17.8 million in 2023, then soared by 391.57% to $87.5 million in 2024, then plummeted by 37.71% to $54.5 million in 2025.
- Its R&D In Process was $54.5 million in Q3 2025, compared to $2.2 million in Q2 2025 and $19.8 million in Q1 2025.